eCommons@AKU
Section of Pulmonary & Critical Care

Department of Medicine

July 2009

Community acquired pneumonia: risk factors
associated with mortality in a tertiary care
hospitalized patients
Muhammad Irfan
Aga Khan University

Syed Fayyaz Hussain
Kettering General Hospital

Khubaib Mapara
Aga Khan University

Shafia Memon
Aga Khan University

Mohammed Mogri
Aga Khan University
See next page for additional authors

Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_med_pulm_critcare
Part of the Infectious Disease Commons, Medical Sciences Commons, Respiratory System
Commons, and the Respiratory Tract Diseases Commons
Recommended Citation
Irfan, M., Hussain, S., Mapara, K., Memon, S., Mogri, M., Bana, M., Malik, A., Khan, S., Khan, N. (2009). Community acquired
pneumonia: risk factors associated with mortality in a tertiary care hospitalized patients. Journal of the Pakistan Medical Association,
59(7), 448-52.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare/9

Authors

Muhammad Irfan, Syed Fayyaz Hussain, Khubaib Mapara, Shafia Memon, Mohammed Mogri, Muniza Bana,
Amna Malik, Sara Khan, and Nadia A Khan

This article is available at eCommons@AKU: http://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare/9

Original Article
Community Acquired Pneumonia: Risk factors associated with
mortality in a tertiary care hospitalized patients

Muhammad Irfan,1 Syed Fayyaz Hussain,2 Khubaib Mapara,3 Shafia Memon,4 Mohammed Mogri,5
Muniza Bana,6 Amna Malik,7 Sara Khan,8 Nadia A. Khan9

Pulmonary Section,1 Medical Student,3-9 Aga Khan University Hospital, Karachi, Pakistan, Kettering General Hospital, United Kingdom.2

Abstract

Objective: To evaluate risk factors associated with mortality in patients hospitalized with Community Acquired Pneumonia
(CAP) from a developing country.
Methods: An observational study was conducted on adult patients admitted with a diagnosis of CAP from January 2002
to August 2003 at Aga Khan University hospital, Karachi, Pakistan. Clinical records were reviewed for demographic
characteristics, clinical and laboratory features, hospital course, and risk factors associated with mortality.
Results: A total of 329 patients (187 males) were admitted with CAP. Two-third of patients had underlying co-morbid
medical illnesses. Complications developed in 15.7% cases and the overall mortality rate was 11%. Risk factors were
identified on initial clinical assessment, laboratory and radiological features and during hospital course. On admission
elevated blood urea, new onset of confusion, abnormal liver function test, low serum albumin, cardiomegaly and presence
of underlying malignancy were strongly associated with increased mortality. Failure to respond to therapy was associated
with a high risk of mortality as depicted by complication during hospital stay (Odds Ratio= 23.3, 95% Confidence Interval=
10.3-52.8), need for mechanical ventilation (OR= 17.1, 95%CI= 7.4-39.8) and need for intensive care unit (OR= 9,
95%CI= 4.2-19.3).
Conclusions: Abnormal liver function test, low albumin and presence of cardiomegaly were more significant mortality risk
factors than age, respiratory rate and blood pressure. Elevated blood urea and confusion remain strong risk factors on
admission. Failure of response to therapy and onset of complications heralded a high risk of death (JPMA 59:448; 2009).
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Introduction

Community acquired pneumonia (CAP) is one of the
leading causes of infectious death in both developed and
developing countries. It is associated with a significant
morbidity and mortality. In a meta-analysis of studies of
prognosis, the short-term mortality in CAP ranged from 5.1%
for patients treated in an ambulatory or hospital setting to
36.5% for patients treated in an intensive care unit.1
Following introduction of antibiotic therapy in the 1940's the
mortality rate from pneumonia decreased sharply but then the
overall mortality rate has either remained stable or increased.2

Despite the high incidence of infectious diseases in
developing countries, there has been little research in
defining risk factors associated with mortality in adult
patients with CAP. Most of the studies on respiratory tract
infections have been done in the paediatric age group and
cannot be used for predicting outcome in the adult
population.3 CURB-65 score and Pneumonia severity index
(PSI) are the two widely used severity assessment tools for
CAP4,5 but the recommendations may not be universally
applicable. The aim of this study was to define clinical
characteristics, hospital course and risk factors associated
with mortality in hospitalized patients with CAP being treated
in a developing country.

Patients and Methods

The study was conducted at Aga Khan University
Hospital, a 450-bedded tertiary care hospital in Karachi,
Pakistan. In this observational study, data was collected on
adult patients (aged 16 or above) admitted between January
2002 and August 2003 with a diagnosis of CAP. Patients were
identified using a computerized database of the hospital
where all diseases are coded using International
Classification of Diseases, 9th Revision with Clinical
Modification (ICD 9CM).

The inclusion criteria for the diagnosis of CAP used
6
were: age 16 Years and above, acute presentation with at
least one major criteria (temperature > 38°C, cough or
expectoration) or at least two minor criteria (pleuritic chest
pain, dyspnea, leukocytosis i.e. white cell count >12,000/mL,
altered mental status, or signs of lung consolidation by
clinical examination). A new infiltrate observed on Chest
Radiograph (CXR).

The exclusion criteria were: patients with clinical or
radiological feature strongly indicative of tuberculosis,
patients transferred from another hospital. patients
developing pneumonia after being hospitalized within the last
2 week for other reason and post-obstructive pneumonia.
A pre-designed structured format was used to gather
data on demographic features, clinical features, co-morbid
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conditions,
laboratory
complications and outcome.

investigations,

treatment,

The primary outcome measure was risk factors
associated with mortality in patients with CAP.

The Statistical package for social science SPSS
(Release 11.0.5, standard version, copyright© SPSS) was
used for data analysis. The descriptive analysis was done for
demographic, clinical and laboratory data. Results were
expressed as mean ± standard deviation, and numbers
(percentages). Findings potentially related with death were
studied by a univariate approach using independent sample ttest, Pearson chi-square and Fisher's exact test wherever
appropriate. Thereafter, a stepwise forward multiple logistic
regression model was applied to the variables found to be
significantly associated with death (p > 0.05 was considered
as statistically significant comparing survivors vs
nonsurvivors. All p-values were two sided.) Multiple
regressions permitted an estimate of the odds ratio of dying
and a calculation of the 95% confidence interval. Patients
who were transferred to another hospital were excluded from
this analysis to make the outcome variable dichotomous
(discharged alive vs. expired).

Results

During the study period 712 patients were admitted
with a principal diagnosis of pneumonia, but 383 were
excluded (156 had aspiration pneumonia, 78 nosocomial
pneumonia, 143 were transferred from another hospital and 6
failed to show a new infiltrate on CXR). Data on 329 cases,
187 (56.8%) males and 142 (43.2%) females, were analyzed
in the final study group.
The mean age of the study group was 62 ± 16.3 years
(range: 18 to 92 years). History of tobacco smoking was
given by 24.3% and alcohol use by 2.4% patients. Co-morbid
medical conditions were present in 63.5% patients (Table 1).

Most patients presented within a week of onset of
symptoms. The common presenting symptoms were fever
(77.5%), chills (77%), and cough (72%). Other symptoms
were dyspnoea (46%), chest pain (23%) and confusion
(14%). Confusion was significantly more common in
patients aged 65 years (p<0.05). On examination, lung
crackles were present in 73% and bronchial breathing in 18%.
Respiratory examination was normal in 34 (10.3%) patients.

Radiographic features revealed lower zones were
affected more frequently than upper zones and bilateral
involvement was seen in 24% of cases. Radiographic changes
included consolidation (36.2%), patchy infiltrates (48.2%),
pleural effusion (23.8%) and atelactasis (7.1%).

Microbiological Specimen:

One or more microbiological specimen was sent in
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Table 1: Co-morbid medical conditions in hospitalized patients
with community acquired pneumonia (n=329).

Cardiovascular diseases
Ischaemic heart disease
Cardiac failure
Hypertension
Pulmonary diseases
Asthma
Chronic obstructive pulmonary disease
Post-tuberculosis
Pulmonary Fibrosis
Bronchiectasis
Lung Cancer
Diabetes Mellitus
Neurological disease
Malignant Neoplasm
Chronic Renal Failure
Chronic Liver Disease
On corticosteroids

Frequency

Percent

150
31
2
117
99
27
32
23
7
7
3
98
31
24
17
12
8

45.60%

30.10%

29.80%
9.40%
7.30%
5.20%
3.60%
2.40%

278 (84.5%) patients. These included blood cultures in 241
(86.7%), sputum in 133 (47.84%), pleural fluid in 23 (8.27%)
and tracheal or bronchial aspirate in 25 (9%) patients. In
about 104 cases (37.4%) both sputum and blood samples
were sent. The yield from various samples included sputum
30.8% (42/133), blood culture 19.5% (47/241), pleural fluid
13.0% (3/23) and tracheal/ bronchial aspirate 60% (12/25).

Streptococcus pneumonia was the commonest
organism identified in 23 (8.3%). Gram-negative organisms
included pseudomonas in 11 (4%), Acinetobacter in 7 (2.5%),
E. coli in 5 (1.8%) and Klebsiella pneumonia in 4 (1.4%)
cases. Other common organisms were staphylococcus aureus
Table 2: Risk factors associated with mortality in hospitalized
patients with community acquired pneumonia (n=319).
Risk Factor
Initial clinic assessment
Age (>65 years)
Underlying malignancy
Dyspnoea
Confusion
Respiratory Rate ?28/min
O2 saturation <90%
Laboratory features
Blood urea nitrogen >20 mg/dl
Abnormal liver function test
Serum Albumin <2.2 gm/dL
Infection with gram negative organisms
Radiological features
Bilateral Involvement
Cardiomegaly
Hospital Course
Complication during hospital stay
Intensive care unit stay required
Ventilatory support Required
450

Odds Ratio

95% Confidenc
Interval

2.2
3.8
2.4
4
2.2
2.9

1.1-4.5
1.3-11.1
1.2-4.5
1.8-8.9
1.1-4.4
1.3-6.4

8.6
4
3.3
2.9

3.2-23.1
1.5-10.6
1.2-9.0
1.2-7.4

2.7
3.9

1.3-5.7
1.3-12.1

23.3
9
17.1

10.3-52.8
4.2-19.3
7.4-39.8

in 7 (2.5%), hemophilus influenza in 5 (1.8%) and moraxella
catarhalis in3 (1.1%). No organism could be isolated in 186
cases (66.91%).

Complications:

Complications during their hospital stay developed in
55 (16.7%) cases. These included parapneumonic effusion in
22 (6.7%), multiple system organ failure in 19 (5.8%),
respiratory failure in 18 (5.5%), septic shock in 17(5.2%),
adult respiratory distress syndrome in 9 (2.7%), empyema in
6 (1.8%), and nosocomial infections in 3 (1%) cases.
Mechanical ventilation was required in 31 (9.4%) of cases, of
these 15(48.3%) died.
The overall mortality was 36 (11%), 283 patients were
discharged (86%) and 10 (3%) patients were transferred to
another hospital.

Using univariate analysis multiple risk factors were
identified at the time of admission and during hospital course.
Independent risk factors associated with mortality in logistic
regression analysis are presented in Table-2. These have been
grouped together so that risk assessment can be performed at
the initial clinical assessment, as laboratory results become
available and during course of hospital stay.

Discussion

Our study has defined the risk factors associated with
mortality in patients hospitalized with community acquired
pneumonia in a developing country. British Thoracic Society
(BTS) recommends CURB-65 score to evaluate severity of
CAP (Table-3). Patients with low score (0-2) are likely to be
Table 3: CURB 65 score to evaluate severity of community
acquired pneumonia.
Score 1 point for each feature present.
Confusion (of new onset)
Urea >42 mg/dl
 Respiratory rate >30/min
 Blood pressure (SBP <90mmHg or DBP < 60mmHg
 Age > 65 years



suitable for home treatment, as the expected mortality is low.
Higher scores (3-5) are associated with increasing mortality
and admission to hospital is recommended.7 Patients should
be assessed for intensive care unit if the score is 4 or 5. Our
study confirmed that on initial assessment confusion,
elevated urea, elevated respiratory rate and age >65 years
were significant risk factors but blood pressure was not an
independent risk factor for mortality. In a similar study from
a Malaysian university hospital, BTS severity assessment
criteria for CAP fared poorly in their patients.8
Pneumonia severity index (PSI) is a more detailed
assessment tool that takes into account age, co-morbid
J Pak Med Assoc

conditions, physical signs, laboratory and radiological
findings. It is more complex but has been validated on over
50,000 patients.5 Both of these validated tools (PSI and
CURB-65) are from developed countries. They are good for
predicting mortality9 only. Our study and Malaysian study
highlights that due to differences in patient population such as
the nutritional status and other co-morbid conditions, severity
criteria validated in western countries may not be universally
applicable.

Our rationale for evaluating serum albumin was to
correlate the nutritional status of patients with mortality from
CAP. In this study, low serum albumin <2.2 g/l was found to
be significantly associated with mortality. Abnormal liver
function test was also associated with increased mortality.
Low albumin level may relate to high prevalence of chronic
ill health secondary to undiagnosed chronic liver disease or
other diseases. Risk association of low albumin and/or
abnormal liver function is in keeping with the finding of other
smaller studies where patients with a low albumin or raised
ALT were significantly more likely to die from their disease
or had prolonged hospital stay.10,11 We recommend liver
function and serum albumin to be checked routinely during
severity assessment of patients hospitalized with CAP in
developing countries.

Bedside evaluation of history and physical signs
supplemented by a chest radiograph would remain the
cornerstone of initial clinical assessment at most treatment
facilities in resource-limited countries. In our study, dyspnea
and bilateral lung involvement on presentation were
associated with a higher mortality. Additionally features of
old age, confusion, underlying malignancy, rapid respiratory
rate and low oxygen saturation should alert the physician for
a more intensive management strategy. Medical centers
admitting patients with CAP should have facility to monitor
blood oxygen saturation using a pulse oximeter as oxygen
saturation <90 % is associated with a worse prognosis.12,13

Knowledge about the causative organisms and their
drug sensitivity pattern has important bearing on the course of
the disease. Streptococcus pneumoniae was the organism
most commonly identified in our study as has been in other
studies worldwide.14,15 Additionally, presence of gramnegative organisms was associated with a higher mortality.
Other studies, have also shown that Gram-negative organisms
are associated with a higher mortality.15,16 The initial
selection of antibiotics should take account of local factors
that indicate risk of drug resistance or likelihood of gramnegative infection.17
In clinical practice culture results are not available
before 48 hours and therefore the initial treatment has to be
empiric. A sound analysis of patient factors and initial
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assessment of CAP severity would help physicians to choose
an appropriate antibiotic regimen. The yield of respiratory
secretions was high but this should be interpreted with
caution. Yield from blood culture was lower but a positive
blood culture represents bactaeremia and has been shown to
be an independent risk factor for mortality.14 In many
resource limited countries facilities for reliable blood culture
are sparse and physicians would have to rely on other
parameters of treatment response. Atypical pathogens (e.g.
Mycoplasma pneumoniae or Chlamydia pneumoniae) may
account for up to 40% of cases of CAP and co-infection may
occur in 16% cases.18 We did not have facilities for
serological testing at the time of the study.
In one study on 260 patients, 80 (31%) had early
clinical failure in response to therapy assessed at day 3.19
Failure to response was defined as death, a need for
mechanical ventilation, respiratory rate >25/min, PaO2 <55
mm Hg, oxygen saturation <90%, haemodynamic instability,
temperature >38ºC or confusion. Patients who failed to
respond had a higher 28-day mortality rate and a longer
hospital stay. In our study, failure to respond to therapy and
development of complications was associated with increased
mortality.

The overall mortality in our study population was
11% and was comparable to that reported in previous
studies.1,15 In a large outcome meta-analysis, the overall
mortality rate in patients with CAP was 13.7%.1 In a study of
pneumonia related death within 90 days of presentation, the
overall mortality was 9%. Of these 53% deaths were assessed
to be pneumonia related and the remaining pneumonia
unrelated.12 Factors independently associated with
pneumonia-related mortality included hypothermia, altered
mental state, increased serum urea nitrogen levels, chronic
liver disease, leucopenia, and hypoxaemia. Increasing age
and evidence of aspiration were independent predictors of
both types of mortality.12
The main weakness of this study is its retrospective
design. Collection of some data was therefore, incomplete.
Other limitations are the higher frequency of elderly patients;
this may not reflect the reality of CAP in our population;
relatively low percentage of positive bacterial culture and
failure to perform serological tests for atypical organisms.

In summary risk factors associated with mortality in
CAP can be identified at the initial assessment and continue
to evolve during hospital course. Greatest risks are
associated with development of complications and need for
mechanical ventilation. This study defines the tools for risk
assessment in a developing country through focused
clinical evaluation and basic investigations. Onset of
complications represents failure of response to therapy and
poor prognosis.
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